PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies

Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer

Dhiraj Yadav, Walter G. Park, Evan Fogel, Liang Li, Suresh T. Chari, Ziding Feng, William E. Fisher, Christopher E. Forsmark, Christie Y. Jeon, Aida Habtezion, Phil A. Hart, Steven J. Hughes, Mohamed O. Othman, Jo Ann S. Rinaudo, Stephen J. Pandol, Temel Tirkes, Jose Serrano, Sudhir Srivastava, Stephen K. Van Den Eeden, David C. Whitcomb & 2 others Mark Topazian, Darwin L. Conwell

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.

Original languageEnglish (US)
Pages (from-to)1229-1238
Number of pages10
JournalPancreas
Volume47
Issue number10
DOIs
StatePublished - Nov 1 2018

Fingerprint

Chronic Pancreatitis
Pancreatic Neoplasms
Disease Progression
Saliva
Observational Studies
Epidemiologic Studies
Cohort Studies
Biomarkers
Urine

Keywords

  • alcohol
  • biorepository
  • cohort
  • genetic
  • pancreas
  • tobacco

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies : Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer. / Yadav, Dhiraj; Park, Walter G.; Fogel, Evan; Li, Liang; Chari, Suresh T.; Feng, Ziding; Fisher, William E.; Forsmark, Christopher E.; Jeon, Christie Y.; Habtezion, Aida; Hart, Phil A.; Hughes, Steven J.; Othman, Mohamed O.; Rinaudo, Jo Ann S.; Pandol, Stephen J.; Tirkes, Temel; Serrano, Jose; Srivastava, Sudhir; Van Den Eeden, Stephen K.; Whitcomb, David C.; Topazian, Mark; Conwell, Darwin L.

In: Pancreas, Vol. 47, No. 10, 01.11.2018, p. 1229-1238.

Research output: Contribution to journalArticle

Yadav, D, Park, WG, Fogel, E, Li, L, Chari, ST, Feng, Z, Fisher, WE, Forsmark, CE, Jeon, CY, Habtezion, A, Hart, PA, Hughes, SJ, Othman, MO, Rinaudo, JAS, Pandol, SJ, Tirkes, T, Serrano, J, Srivastava, S, Van Den Eeden, SK, Whitcomb, DC, Topazian, M & Conwell, DL 2018, 'PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer', Pancreas, vol. 47, no. 10, pp. 1229-1238. https://doi.org/10.1097/MPA.0000000000001170
Yadav, Dhiraj ; Park, Walter G. ; Fogel, Evan ; Li, Liang ; Chari, Suresh T. ; Feng, Ziding ; Fisher, William E. ; Forsmark, Christopher E. ; Jeon, Christie Y. ; Habtezion, Aida ; Hart, Phil A. ; Hughes, Steven J. ; Othman, Mohamed O. ; Rinaudo, Jo Ann S. ; Pandol, Stephen J. ; Tirkes, Temel ; Serrano, Jose ; Srivastava, Sudhir ; Van Den Eeden, Stephen K. ; Whitcomb, David C. ; Topazian, Mark ; Conwell, Darwin L. / PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies : Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer. In: Pancreas. 2018 ; Vol. 47, No. 10. pp. 1229-1238.
@article{303bbc4398a04fa68ba48fd66049b721,
title = "PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer",
abstract = "Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.",
keywords = "alcohol, biorepository, cohort, genetic, pancreas, tobacco",
author = "Dhiraj Yadav and Park, {Walter G.} and Evan Fogel and Liang Li and Chari, {Suresh T.} and Ziding Feng and Fisher, {William E.} and Forsmark, {Christopher E.} and Jeon, {Christie Y.} and Aida Habtezion and Hart, {Phil A.} and Hughes, {Steven J.} and Othman, {Mohamed O.} and Rinaudo, {Jo Ann S.} and Pandol, {Stephen J.} and Temel Tirkes and Jose Serrano and Sudhir Srivastava and {Van Den Eeden}, {Stephen K.} and Whitcomb, {David C.} and Mark Topazian and Conwell, {Darwin L.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1097/MPA.0000000000001170",
language = "English (US)",
volume = "47",
pages = "1229--1238",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies

T2 - Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer

AU - Yadav, Dhiraj

AU - Park, Walter G.

AU - Fogel, Evan

AU - Li, Liang

AU - Chari, Suresh T.

AU - Feng, Ziding

AU - Fisher, William E.

AU - Forsmark, Christopher E.

AU - Jeon, Christie Y.

AU - Habtezion, Aida

AU - Hart, Phil A.

AU - Hughes, Steven J.

AU - Othman, Mohamed O.

AU - Rinaudo, Jo Ann S.

AU - Pandol, Stephen J.

AU - Tirkes, Temel

AU - Serrano, Jose

AU - Srivastava, Sudhir

AU - Van Den Eeden, Stephen K.

AU - Whitcomb, David C.

AU - Topazian, Mark

AU - Conwell, Darwin L.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.

AB - Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.

KW - alcohol

KW - biorepository

KW - cohort

KW - genetic

KW - pancreas

KW - tobacco

UR - http://www.scopus.com/inward/record.url?scp=85055078667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055078667&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001170

DO - 10.1097/MPA.0000000000001170

M3 - Article

VL - 47

SP - 1229

EP - 1238

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 10

ER -